Editorial
A new era of treating advanced lung cancer is upon us
Abstract
From the adaption of chemotherapy in the 1990’s after the landmark meta-analysis (1) to the pivotal randomized trial pointing to “dealer’s choice” for platinum-doublet regimens (2), followed by treatment refinement using molecular profiling and targeted therapy for defined sub-populations (3,4), we now have the emergence of a new era to treat advanced non-small cell lung cancer (NSCLC).
